Press Release

Jan, 10 2024

Revolutionizing Medicine: The Impact and Advancements of Biologics in Modern Healthcare and Therapeutics

The Asia-Pacific biologics market thrives in the pharmaceutical industry, focusing on drugs derived from living organisms. With unique advantages over traditional medications, biologics boast target specificity, reducing side effects. These drugs, such as Rituximab, a chimeric monoclonal antibody, have revolutionized treatments for serious illnesses such as non-Hodgkin's lymphoma. Their development signifies a paradigm shift in healthcare, providing effective and tailored therapeutic solutions and garnering increased demand from healthcare professionals in the Asia-Pacific region.

Access Full Report @

Data Bridge Market Research analyses that the Asia-Pacific Biologics Market, which was USD 59,138.53 million in 2022, is expected to reach USD 1,41,276.35 million by 2030 and is expected to undergo a CAGR of 11.5% during the forecast period from 2023-2030. The increasing aging population in the Asia-Pacific region fuels the demand for biologics to manage the heightened occurrence of diseases associated with aging, emphasizing the crucial role of biologics in healthcare.

Key Findings of the Study

Asia-Pacific Biologics Market

Increased incidence of chronic diseases is expected to drive the market's growth rate

Globally, chronic diseases, claiming about 40 million lives annually, pose a major health concern. In Asia, 8.5 million lives are affected, with cardiovascular diseases, diabetes, cancer, and respiratory conditions being prevalent. This rise is attributed to aging populations and unhealthy lifestyle choices, including limited physical activity and tobacco/alcohol consumption. The surge in chronic diseases drives demand for advanced biologic therapies, providing targeted and effective treatments, and addressing a pressing healthcare need in the Asia-Pacific region.

Report Scope and Market Segmentation

Report Metric


Forecast Period

2023 to 2030

Base Year


Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Class (Tumor Necrosis Factor-Α (TNF) Inhibitors, B-Cell Inhibitors, Interleukin Inhibitors, Selective Co-Stimulation Modulators (Abatacept), and Others), Type (Monoclonal Antibodies (MABs), Therapeutic Proteins, Vaccines, Cellular Based Biologics, Gene Based Biologics, and Others), Route of Administration (Injection and Infusion), Application (Oncology, Autoimmune Diseases, Diabetes, Infectious Diseases, Cardiovascular Diseases, Ophthalmic Conditions, Dermatological Diseases, and Others), Source Material (Humans, Avian Cell Culture, Yeast, Bacteria, Insects Cell Culture, Transgenics, and Others), End User (Hospitals, Specialty Clinics, Academics and Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Third Party Distribution).

Countries Covered

China, Japan, India, Australia, South Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam, and rest of Asia-Pacific.

Market Players Covered

AbbVie Inc. (U.S.), AGC Biologics (U.S.), BeiGene (China), Bharat Biotech (India), BioDiem (Australia), Biogen (U.S.), Biocon (India), Bristol-Myers Squibb Company (U.S.), Catalent, Inc. (U.S.), Celltrion Healthcare Co., Ltd. (South Korea), CHIME BIOLOGICS (China), Cipla Inc. (India), F. Hoffmann-La Roche Ltd. (Switzerland), FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. (Japan), GlaxoSmithKline plc. (U.K.), Innovent (China), Intas Pharmaceutical Ltd. (India), Ipsen Pharma (France), Johnson & Johnson Services, Inc. (U.S.), KM Biologics (South Korea), MERCK & CO., INC. (U.S.), NBHL ltd. (India), Panacea Biotec (India), Pfizer Inc. (U.S.), Qilu Pharmaceutical Co., Ltd. (China), Serum Institute of India Pvt. Ltd. (India), Shanghai Henlius Biotech, Inc. (China), Teva Pharmaceutical Industries Ltd. (Israel), WuXi Biologics (China), YL Biologics (China) among others            

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The Asia-Pacific biologics market is segmented on the basis of class, type, route of administration, application, source material, end user, and distribution channel.

  • On the basis of class, the Asia-Pacific biologics market is segmented into tumor necrosis factor-α (TNF) inhibitors, b-cell inhibitors, interleukin inhibitors, selective co-stimulation modulators (abatacept), and others
  • On the basis of type, the Asia-Pacific biologics market is segmented into monoclonal antibodies (mABs), therapeutic proteins, vaccines, cellular based biologics, gene based biologics, and other
  • On the basis of route of administration, the Asia-Pacific biologics market is segmented into injection, and infusion
  • On the basis of application, the Asia-Pacific biologics market is segmented into oncology, autoimmune diseases, diabetes, infectious diseases, cardiovascular diseases, ophthalmic conditions, dermatological diseases, and others
  • On the basis of source material, the Asia-Pacific biologics market is segmented into humans, avian cell culture, yeast, bacteria, insect cell culture, transgenics, and others
  • On the basis of end user, the Asia-Pacific biologics market is segmented into hospitals, specialty clinics, academics and research institutes, and others
  • On the basis of distribution channel, the Asia-Pacific biologics market is segmented into direct tender, retail sales, and third party distribution

Major Players

Data Bridge Market Research recognizes the following companies as the major Asia-Pacific biologics market players in Asia-Pacific biologics market are AbbVie Inc. (U.S.), AGC Biologics (U.S.), BeiGene (China), Bharat Biotech (India), BioDiem (Australia), Biogen (U.S.), Biocon (India), Bristol-Myers Squibb Company (U.S.), Catalent, Inc. (U.S.), Celltrion Healthcare Co., Ltd. (South Korea), CHIME BIOLOGICS (China), Cipla Inc. (India)

Asia-Pacific Biologics Market

Market Developments

  • In February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson gained FDA approval for CARVYKTI (ciltacabtagene autoleucel) to treat relapsed or refractory multiple myeloma in adults who have undergone four or more prior lines of therapy, including specific medications. This biologic medicine marks a significant advancement in addressing the challenges of this complex hematologic malignancy
  • In June 2021, the Japanese Ministry of Health, Labour, and Welfare approved the commercialization of MIMEDX's Epifix in Japan. This regulatory milestone allows MIMEDX, a U.S.-based company, to introduce Epifix to the Japanese market, offering innovative solutions in the field of regenerative medicine
  • In January 2021, Integra LifeSciences, based in the U.S., completed the acquisition of ACell, Inc. This strategic move enhances Integra's wound management portfolio, broadening its offerings for treating complex wounds with comprehensive and advanced solutions
  • In November 2020, Stryker Corporation, a U.S.-based medical technology company, successfully acquired Wright Medical Group N.V. This acquisition, involving a renowned Netherlands-based medical devices company specializing in extremities and biologics, strengthens Stryker's global position and expands its capabilities to deliver improved medical solutions in extremities and biologics worldwide

Regional Analysis

Geographically, the countries covered in the Asia-Pacific biologics market report are China, Japan, India, Australia, South Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam, and rest of Asia-Pacific

As per Data Bridge Market Research analysis:

China is estimated to be the fastest-growing region in Asia-Pacific biologics market during the forecast period 2023-2030

China is expected to dominate the Asia-Pacific biologics market, driven by a surge in chronic diseases such as diabetes and cancer. Recent advancements in biologics further contribute to China's prominent position in the market. The nation's commitment to healthcare innovation and research, coupled with a vast population affected by chronic conditions, positions it as a key player in shaping the landscape of biologics in the Asia-Pacific region.

For more detailed information about the Asia-Pacific biologics market report, click here –

Client Testimonials